Advances in bio-immunotherapy for castration-resistant prostate cancer
Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in Ch...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2023-11, Vol.149 (14), p.13451-13458 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 13458 |
|---|---|
| container_issue | 14 |
| container_start_page | 13451 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 149 |
| creator | Lin, Canling Chen, Yonghui Shi, Liji Lin, Huarong Xia, Hongmei Yin, Weihua |
| description | Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer. |
| doi_str_mv | 10.1007/s00432-023-05152-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2839248134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3153551273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-743d9074dab37e86f29e4e8ce02a938d0d632242142221f77399b2891a77c53d3</originalsourceid><addsrcrecordid>eNqFkc1OwzAQhC0EoqXwAhxQJC5cDPauHcfHqqKAVIkLnC03cSBVkxQ7Qerb45ICEgc4-We_mdFqCDnn7Jozpm4CYwKBMkDKJJdA9QEZ890XR5SHZMy44lQCT0fkJIQVi2-p4JiMUImUZUyNyXxavNsmdyGpmmRZtbSq675pu1fn7WablK1Pchs6b7uqbah3oQqdbbpk49t46VycRrU_JUelXQd3tj8n5Hl--zS7p4vHu4fZdEFzlLqjSmChmRKFXaJyWVqCdsJluWNgNWYFK1IEEMAFAPBSKdR6CZnmVqlcYoETcjX4xvy33oXO1FXI3XptG9f2wSCXKCUHhf-ikKEGkXEUEb38ha7a3jdxkUipGC9FqiMFA5XH3YN3pdn4qrZ-azgzu0LMUIiJhZjPQsxOdLG37pe1K74lXw1EAAcgxFHz4vxP9h-2H_nRk9U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878915469</pqid></control><display><type>article</type><title>Advances in bio-immunotherapy for castration-resistant prostate cancer</title><source>Springer Nature - Complete Springer Journals</source><creator>Lin, Canling ; Chen, Yonghui ; Shi, Liji ; Lin, Huarong ; Xia, Hongmei ; Yin, Weihua</creator><creatorcontrib>Lin, Canling ; Chen, Yonghui ; Shi, Liji ; Lin, Huarong ; Xia, Hongmei ; Yin, Weihua</creatorcontrib><description>Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-023-05152-9</identifier><identifier>PMID: 37460807</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>androgens ; Cancer Research ; Cancer therapies ; Castration ; Chemotherapy ; cytokines ; drug therapy ; Endocrine therapy ; Hematology ; Immune checkpoint inhibitors ; Immunotherapy ; Internal Medicine ; Life span ; longevity ; Medicine ; Medicine & Public Health ; Microenvironments ; Oncology ; Prostate cancer ; prostatic neoplasms ; Radiation therapy ; radiotherapy ; Review ; taxanes</subject><ispartof>Journal of cancer research and clinical oncology, 2023-11, Vol.149 (14), p.13451-13458</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-743d9074dab37e86f29e4e8ce02a938d0d632242142221f77399b2891a77c53d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-023-05152-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-023-05152-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37460807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Canling</creatorcontrib><creatorcontrib>Chen, Yonghui</creatorcontrib><creatorcontrib>Shi, Liji</creatorcontrib><creatorcontrib>Lin, Huarong</creatorcontrib><creatorcontrib>Xia, Hongmei</creatorcontrib><creatorcontrib>Yin, Weihua</creatorcontrib><title>Advances in bio-immunotherapy for castration-resistant prostate cancer</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer.</description><subject>androgens</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Castration</subject><subject>Chemotherapy</subject><subject>cytokines</subject><subject>drug therapy</subject><subject>Endocrine therapy</subject><subject>Hematology</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Life span</subject><subject>longevity</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microenvironments</subject><subject>Oncology</subject><subject>Prostate cancer</subject><subject>prostatic neoplasms</subject><subject>Radiation therapy</subject><subject>radiotherapy</subject><subject>Review</subject><subject>taxanes</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc1OwzAQhC0EoqXwAhxQJC5cDPauHcfHqqKAVIkLnC03cSBVkxQ7Qerb45ICEgc4-We_mdFqCDnn7Jozpm4CYwKBMkDKJJdA9QEZ890XR5SHZMy44lQCT0fkJIQVi2-p4JiMUImUZUyNyXxavNsmdyGpmmRZtbSq675pu1fn7WablK1Pchs6b7uqbah3oQqdbbpk49t46VycRrU_JUelXQd3tj8n5Hl--zS7p4vHu4fZdEFzlLqjSmChmRKFXaJyWVqCdsJluWNgNWYFK1IEEMAFAPBSKdR6CZnmVqlcYoETcjX4xvy33oXO1FXI3XptG9f2wSCXKCUHhf-ikKEGkXEUEb38ha7a3jdxkUipGC9FqiMFA5XH3YN3pdn4qrZ-azgzu0LMUIiJhZjPQsxOdLG37pe1K74lXw1EAAcgxFHz4vxP9h-2H_nRk9U</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Lin, Canling</creator><creator>Chen, Yonghui</creator><creator>Shi, Liji</creator><creator>Lin, Huarong</creator><creator>Xia, Hongmei</creator><creator>Yin, Weihua</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20231101</creationdate><title>Advances in bio-immunotherapy for castration-resistant prostate cancer</title><author>Lin, Canling ; Chen, Yonghui ; Shi, Liji ; Lin, Huarong ; Xia, Hongmei ; Yin, Weihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-743d9074dab37e86f29e4e8ce02a938d0d632242142221f77399b2891a77c53d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>androgens</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Castration</topic><topic>Chemotherapy</topic><topic>cytokines</topic><topic>drug therapy</topic><topic>Endocrine therapy</topic><topic>Hematology</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Life span</topic><topic>longevity</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microenvironments</topic><topic>Oncology</topic><topic>Prostate cancer</topic><topic>prostatic neoplasms</topic><topic>Radiation therapy</topic><topic>radiotherapy</topic><topic>Review</topic><topic>taxanes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Canling</creatorcontrib><creatorcontrib>Chen, Yonghui</creatorcontrib><creatorcontrib>Shi, Liji</creatorcontrib><creatorcontrib>Lin, Huarong</creatorcontrib><creatorcontrib>Xia, Hongmei</creatorcontrib><creatorcontrib>Yin, Weihua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Canling</au><au>Chen, Yonghui</au><au>Shi, Liji</au><au>Lin, Huarong</au><au>Xia, Hongmei</au><au>Yin, Weihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in bio-immunotherapy for castration-resistant prostate cancer</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>149</volume><issue>14</issue><spage>13451</spage><epage>13458</epage><pages>13451-13458</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37460807</pmid><doi>10.1007/s00432-023-05152-9</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2023-11, Vol.149 (14), p.13451-13458 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2839248134 |
| source | Springer Nature - Complete Springer Journals |
| subjects | androgens Cancer Research Cancer therapies Castration Chemotherapy cytokines drug therapy Endocrine therapy Hematology Immune checkpoint inhibitors Immunotherapy Internal Medicine Life span longevity Medicine Medicine & Public Health Microenvironments Oncology Prostate cancer prostatic neoplasms Radiation therapy radiotherapy Review taxanes |
| title | Advances in bio-immunotherapy for castration-resistant prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A46%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20bio-immunotherapy%20for%20castration-resistant%20prostate%20cancer&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Lin,%20Canling&rft.date=2023-11-01&rft.volume=149&rft.issue=14&rft.spage=13451&rft.epage=13458&rft.pages=13451-13458&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-023-05152-9&rft_dat=%3Cproquest_cross%3E3153551273%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2878915469&rft_id=info:pmid/37460807&rfr_iscdi=true |